Management for Phototoxicity after Photodynamic Therapy Using Talaporfin Sodium

DOI Web Site 1 Citations 12 References Open Access
  • Tamaoki Masashi
    Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine
  • Ohashi Shinya
    Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine
  • Hirohashi Kenshiro
    Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine
  • Yoshioka Masahiro
    Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine
  • Amanuma Yusuke
    Department of Clinical Trial Promotion, Chiba Cancer Center
  • Muto Manabu
    Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine

Bibliographic Information

Other Title
  • レザフィリンPDTにおける光線過敏症対策

Search this article

Description

<p>Photodynamic therapy (PDT) using talaporfin sodium and PD laser (talaporfin-PDT) has been reported as an effective treatment for malignant diseases due to the high tumor accumulation of talaporfin sodium and the prolonged attainable depth of PD laser (wavelength: 664 nm). Talaporfin-PDT has been clinically applied as treatment for early stage lung cancer, primary malignant brain tumor, and salvage treatment for local failure after chemoradiotherapy (CRT) or radiotherapy (RT) in patients with esophageal cancer in Japan. Skin phototoxicity is the most important complication in PDT. Talaporfin sodium has a lower risk of skin phototoxicity compared with porfimer sodium, and requires shorter sun shade preriod (2 weeks vs 1 month). However, skin phototoxicity has been reported (0–14.8%) in some clinical trials using talaporfin-PDT. Therefore management for skin phototoxicity is essential in the treatment of talaporfin-PDT. In this article, we describe the management method for a skin phototoxicity after talaporfin-PDT in our hospital.</p>

Journal

Citations (1)*help

See more

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top